Full-Time
Develops gene editing treatments using CRISPR
No salary listed
Mid, Senior
Cambridge, MA, USA
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create effective and lasting therapies that can enhance the quality of life for patients suffering from serious health conditions. Unlike many competitors, Editas Medicine has a diverse pipeline of experimental medicines and actively shares clinical data to engage with the medical community. Their goal is to provide transformative treatments for patients worldwide.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Tuition Reimbursement
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Plan
Wellness Program
Unlimited Paid Time Off
Amy Parsion Senior Vice President of Finance Amy Parison Appointed CFOErick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer.“We are thrilled to promote Amy to the executive leadership team as our new CFO
Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr
Following Lucera's departure, Editas has appointed Amy Parison, the current Senior Vice President of Finance, as the new Senior Vice President, Chief Financial Officer, and Treasurer.
Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings.
Editas is shifting focus to developing in-vivo treatments that edit stem cells inside the human body after recent pre-clinical data showed promise in blood-forming stem cells and the liver, and plans to share data and development timelines in the first quarter of 2025.